Showing results (851-860 of 1,384) with videos related to
Sort By:
Pageof 139
Clinical Biomechanics (Bristol, Avon)|December 14, 2011
An ex vivo biomechanical comparison of a novel vertebral compression fracture treatment system to kyphoplastyDerek C Wilson, Ryan J Connolly, Qingan Zhu, et al.Journal of the American College of Emergency Physicians Open|March 14, 2022
Thirty-day mortality with andexanet alfa compared with prothrombin complex concentrate therapy for life-threatening direct oral anticoagulant-related bleedingAlexander T Cohen, Megan Lewis, Augusta Connor, et al.Journal of Neural Engineering|April 16, 2021
Multi-objective data-driven optimization for improving deep brain stimulation in Parkinson's diseaseMark J Connolly, Eric R Cole, Faical Isbaine, et al.Drug Testing and Analysis|October 30, 2023
In vitro cannabinoid activity profiling of generic ban-evading brominated synthetic cannabinoid receptor agonists and their analogsMarie H Deventer, Mattias Persson, Caitlyn Norman, et al.International Journal of Cardiology|May 15, 2007
Potential demographic and baselines variables for risk stratification of high-risk post-myocardial infarction patients in the era of implantable cardioverter-defibrillator--a prognostic indicatorYee Guan Yap, Trinh Duong, Martin Bland, et al.FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|May 29, 2007
Endogenous endostatin inhibits choroidal neovascularizationAlexander G Marneros, Haicheng She, Hadi Zambarakji, et al.The American Journal of Cardiology|July 11, 2006
Efficacy of azimilide for the maintenance of sinus rhythm in patients with paroxysmal atrial fibrillation in the presence and absence of structural heart diseaseCharles R Kerr, Stuart J Connolly, Peter Kowey, et al.The New England Journal of Medicine|December 14, 2004
Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarctionStefan H Hohnloser, Karl Heinz Kuck, Paul Dorian, et al.American Heart Journal|December 19, 2015
Interleukin-6 and C-reactive protein and risk for death and cardiovascular events in patients with atrial fibrillationJulia Aulin, Agneta Siegbahn, Ziad Hijazi, et al.TH Open : Companion Journal to Thrombosis and Haemostasis|June 29, 2019
Apixaban-Calibrated Anti-FXa Activity in Relation to Outcome Events and Clinical Characteristics in Patients with Atrial Fibrillation: Results from the AVERROES TrialVinai C Bhagirath, John W Eikelboom, Jack Hirsh, et al.Pageof 139